Current and Developing Treatments to Target EGFR for NSCLC
DOI:
https://doi.org/10.47611/jsrhs.v13i2.6740Keywords:
Non-Small Cell Lung Cancer, NSCLC, EGFR, The Epidermal Growth Pathway Receptor, Chemotherapy, Radiation Therapy, Immunotherapy, Car-T, Chimeric Antigen Receptor T cell therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Cas9, CRISPRAbstract
Lung cancer is amongst the most diagnosed cancers with a relatively low five-year survival rate of around 20 percent. Currently, the most frequent first-line treatments for lung cancer, more specifically non-small cell lung cancer, consist of chemotherapy, radiation therapy, target therapy, and immunotherapy. However, challenges such as the high cost of treatment, drug resistance, and immunosuppressive tumor microenvironment make it difficult to treat the cancer effectively. While researching ways to overcome these challenges, new treatments involving CAR-T therapy which has shown promise in treating blood cancer, and CRISPR which has shown the precise targeting of genes are being developed intensively. This review will delve into the EGFR gene, and how targeting it could improve the prognosis due to its prevalence in patients diagnosed with NSCLC. Overall, this review will detail the advantages and disadvantages of each of the current treatments for NSCLC and present new treatments like CAR-T and CRISPR for NSCLC.
Downloads
References or Bibliography
Altun, İ., & Sonkaya, A. (2018). The Most Common Side Effects Experienced by Patients Were Receiving First Cycle of Chemotherapy. Iranian Journal of Public Health, 47(8), 1218–1219. https://pubmed.ncbi.nlm.nih.gov/30186799/
Basumallik, N., & Agarwal, M. (2023). Small Cell Lung Cancer. https://www.ncbi.nlm.nih.gov/books/NBK482458/
Brown, A., Kumar, S., & Tchounwou, P. B. (2019). Cisplatin-Based Chemotherapy of Human Cancers. Journal of Cancer Science & Therapy, 11(4). https://pubmed.ncbi.nlm.nih.gov/32148661/
Gerber, D. E. (2008). Targeted Therapies: A New Generation of Cancer Treatments. www.aafp.org/afp.
Graham, R. P., Treece, A. L., Lindeman, N. I., Vasalos, P., Shan, , Mu, Jennings, L. J., & Rimm, D. L. (2018). Worldwide Frequency of Commonly Detected EGFR Mutations. Archives of Pathology & Laboratory Medicine, 142(2), 163–167. https://doi.org/10.5858/arpa.2016-0579-CP
Iyer, S., Roughley, A., Rider, A., & Taylor-Stokes, G. (2014). The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Supportive Care in Cancer, 22(1), 181–187. https://doi.org/10.1007/s00520-013-1959-4
Ke, X., & Shen, L. (2017). Molecular targeted therapy of cancer: The progress and future prospect. Frontiers in Laboratory Medicine, 1(2), 69–75. https://doi.org/10.1016/j.flm.2017.06.001
Kim, C. S., & Jeter, M. D. (2023). Radiation Therapy for Early Stage Non-Small Cell Lung Cancer.
Luqmani, Y. A. (2005). Mechanisms of Drug Resistance in Cancer Chemotherapy. Medical Principles and Practice, 14(Suppl. 1), 35–48. https://doi.org/10.1159/000086183
Miller, B. A., Chu, K. C., Hankey, B. F., & Ries, L. A. G. (2008). Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes & Control : CCC, 19(3), 227–256. https://doi.org/10.1007/s10552-007-9088-3
Ochi, T., Maruta, M., Tanimoto, K., Kondo, F., Yamamoto, T., Kurata, M., Fujiwara, H., Masumoto, J., Takenaka, K., & Yasukawa, M. (2021). A single-chain antibody generation system yielding CAR-T cells with superior antitumor function. Communications Biology, 4(1), 273. https://doi.org/10.1038/s42003-021-01791-1
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., & Yokoyama, S. (2002). Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains. Cell, 110(6), 775–787. https://doi.org/10.1016/S0092-8674(02)00963-7
PDQ Adult Treatment Editorial Board. (2002). Non-Small Cell Lung Cancer Treatment (PDQ®): Patient Version.
Redman, M., King, A., Watson, C., & King, D. (2016). What is CRISPR/Cas9? Archives of Disease in Childhood. Education and Practice Edition, 101(4), 213–215. https://doi.org/10.1136/archdischild-2016-310459
Rude Voldborg, B., Damstrup, L., Spang-Thomsen, M., & Skovgaard Poulsen, H. (1997a). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 8(12), 1197–1206. https://doi.org/10.1023/A:1008209720526
Rude Voldborg, B., Damstrup, L., Spang-Thomsen, M., & Skovgaard Poulsen, H. (1997b). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 8(12), 1197–1206. https://doi.org/10.1023/A:1008209720526
Sigismund, S., Avanzato, D., & Lanzetti, L. (2018). Emerging functions of the EGFR in cancer. Molecular Oncology, 12(1), 3–20. https://doi.org/10.1002/1878-0261.12155
Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal, 11(4), 69. https://doi.org/10.1038/s41408-021-00459-7
Stewart, E. L., Tan, S. Z., Liu, G., & Tsao, M.-S. (2015). Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Translational Lung Cancer Research, 4(1), 67–81. https://doi.org/10.3978/j.issn.2218-6751.2014.11.06
Tanaka, T., Matsuoka, M., Sutani, A., Gemma, A., Maemondo, M., Inoue, A., Okinaga, S., Nagashima, M., Oizumi, S., Uematsu, K., Nagai, Y., Moriyama, G., Miyazawa, H., Ikebuchi, K., Morita, S., Kobayashi, K., & Hagiwara, K. (2010). Frequency of and variables associated with the EGFR mutation and its subtypes. International Journal of Cancer, 126(3), 651–655. https://doi.org/10.1002/ijc.24746
Tang, H., & Shrager, J. B. (2016a). CRISPR /Cas‐mediated genome editing to treat EGFR ‐mutant lung cancer: a personalized molecular surgical therapy. EMBO Molecular Medicine, 8(2), 83–85. https://doi.org/10.15252/emmm.201506006
Tang, H., & Shrager, J. B. (2016b). CRISPR /Cas‐mediated genome editing to treat EGFR ‐mutant lung cancer: a personalized molecular surgical therapy. EMBO Molecular Medicine, 8(2), 83–85. https://doi.org/10.15252/emmm.201506006
Tormoen, G. W., Crittenden, M. R., & Gough, M. J. (2018). Role of the immunosuppressive microenvironment in immunotherapy. Advances in Radiation Oncology, 3(4), 520–526. https://doi.org/10.1016/j.adro.2018.08.018
Vincent, R. L., Gurbatri, C. R., Redenti, A., Coker, C., Arpaia, N., Danino, T., & Affiliations, †. (n.d.). Probiotic-guided CAR-T cells for universal solid tumor targeting. https://doi.org/10.1101/2021.10.10.463366
Walsh, V., & Goodman, J. (1999). Cancer chemotherapy, biodiversity, public and private property: the case of the anti-cancer drug Taxol. Social Science & Medicine, 49(9), 1215–1225. https://doi.org/10.1016/S0277-9536(99)00161-6
Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance (Alhambra, Calif.), 2(2), 141–160. https://doi.org/10.20517/cdr.2019.10
Yang, L., Wang, L., & Zhang, Y. (2016). Immunotherapy for lung cancer: advances and prospects. American Journal of Clinical and Experimental Immunology, 5(1), 1–20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858602/
Zappa, C., & Mousa, S. A. (2016a). Non-small cell lung cancer: Current treatment and future advances. Translational Lung Cancer Research, 5(3), 288–300. https://doi.org/10.21037/tlcr.2016.06.07
Zappa, C., & Mousa, S. A. (2016b). Non-small cell lung cancer: current treatment and future advances. Translational Lung Cancer Research, 5(3), 288–300. https://doi.org/10.21037/tlcr.2016.06.07
Zarogoulidis, K., Zarogoulidis, P., Darwiche, K., Boutsikou, E., Machairiotis, N., Tsakiridis, K., Katsikogiannis, N., Kougioumtzi, I., Karapantzos, I., Huang, H., & Spyratos, D. (2013). Treatment of non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 5 Suppl 4(Suppl 4), S389-96. https://doi.org/10.3978/j.issn.2072-1439.2013.07.10
Zhang, Y.-L., Yuan, J.-Q., Wang, K.-F., Fu, X.-H., Han, X.-R., Threapleton, D., Yang, Z.-Y., Mao, C., & Tang, J.-L. (2016). The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget, 7(48), 78985–78993. https://doi.org/10.18632/oncotarget.12587
Published
How to Cite
Issue
Section
Copyright (c) 2024 Linda Luo; Dan Wang
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
